Literature DB >> 24797941

Investigating the effects of probiotics on pneumococcal colonization using an in vitro adherence assay.

Eileen M Dunne1, Zheng Q Toh2, Mary John3, Jayne Manning4, Catherine Satzke4, Paul Licciardi2.   

Abstract

Adherence of Streptococcus pneumoniae (the pneumococcus) to the epithelial lining of the nasopharynx can result in colonization and is considered a prerequisite for pneumococcal infections such as pneumonia and otitis media. In vitro adherence assays can be used to study the attachment of pneumococci to epithelial cell monolayers and to investigate potential interventions, such as the use of probiotics, to inhibit pneumococcal colonization. The protocol described here is used to investigate the effects of the probiotic Streptococcus salivarius on the adherence of pneumococci to the human epithelial cell line CCL-23 (sometimes referred to as HEp-2 cells). The assay involves three main steps: 1) preparation of epithelial and bacterial cells, 2) addition of bacteria to epithelial cell monolayers, and 3) detection of adherent pneumococci by viable counts (serial dilution and plating) or quantitative real-time PCR (qPCR). This technique is relatively straightforward and does not require specialized equipment other than a tissue culture setup. The assay can be used to test other probiotic species and/or potential inhibitors of pneumococcal colonization and can be easily modified to address other scientific questions regarding pneumococcal adherence and invasion.

Entities:  

Mesh:

Year:  2014        PMID: 24797941      PMCID: PMC4181538          DOI: 10.3791/51069

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  18 in total

1.  In vitro assay of bacterial adhesion onto mammalian epithelial cells.

Authors:  Jason Letourneau; Cynthia Levesque; Frederic Berthiaume; Mario Jacques; Michael Mourez
Journal:  J Vis Exp       Date:  2011-05-16       Impact factor: 1.355

Review 2.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

3.  Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells.

Authors:  Edith L G M Tonnaer; Theo G Hafmans; Toine H Van Kuppevelt; Elisabeth A M Sanders; Paul E Verweij; Jo H A J Curfs
Journal:  Microbes Infect       Date:  2005-09-16       Impact factor: 2.700

4.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

Review 5.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease.

Authors:  D Bogaert; R De Groot; P W M Hermans
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

6.  Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA.

Authors:  Maria da Gloria S Carvalho; Maria Lucia Tondella; Karen McCaustland; Luciana Weidlich; Lesley McGee; Leonard W Mayer; Arnold Steigerwalt; Melissa Whaley; Richard R Facklam; Barry Fields; George Carlone; Edwin W Ades; Ron Dagan; Jacquelyn S Sampson
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

Review 7.  Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics.

Authors:  Philip A Wescombe; Nicholas C K Heng; Jeremy P Burton; Chris N Chilcott; John R Tagg
Journal:  Future Microbiol       Date:  2009-09       Impact factor: 3.165

8.  Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome.

Authors:  Paul V Licciardi; Zheng Quan Toh; Eileen Dunne; Sook-San Wong; Edward K Mulholland; Mimi Tang; Roy M Robins-Browne; Catherine Satzke
Journal:  PLoS Pathog       Date:  2012-06-07       Impact factor: 6.823

9.  Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants.

Authors:  Brenda A Kwambana; Michael R Barer; Christian Bottomley; Richard A Adegbola; Martin Antonio
Journal:  BMC Infect Dis       Date:  2011-06-20       Impact factor: 3.090

10.  Inhibition of Streptococcus pneumoniae adherence to human epithelial cells in vitro by the probiotic Lactobacillus rhamnosus GG.

Authors:  Sook-San Wong; Zheng Quan Toh; Eileen M Dunne; E Kim Mulholland; Mimi L K Tang; Roy M Robins-Browne; Paul V Licciardi; Catherine Satzke
Journal:  BMC Res Notes       Date:  2013-04-05
View more
  4 in total

1.  Lacticaseibacillus casei AMBR2 modulates the epithelial barrier function and immune response in a donor-derived nasal microbiota manner.

Authors:  Charlotte De Rudder; Cristina Garcia-Tímermans; Ilke De Boeck; Sarah Lebeer; Tom Van de Wiele; Marta Calatayud Arroyo
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

2.  Investigation of Streptococcus salivarius-mediated inhibition of pneumococcal adherence to pharyngeal epithelial cells.

Authors:  Jayne Manning; Eileen M Dunne; Philip A Wescombe; John D F Hale; E Kim Mulholland; John R Tagg; Roy M Robins-Browne; Catherine Satzke
Journal:  BMC Microbiol       Date:  2016-09-29       Impact factor: 3.605

Review 3.  Modelling upper respiratory tract diseases: getting grips on host-microbe interactions in chronic rhinosinusitis using in vitro technologies.

Authors:  Charlotte De Rudder; Marta Calatayud Arroyo; Sarah Lebeer; Tom Van de Wiele
Journal:  Microbiome       Date:  2018-04-24       Impact factor: 14.650

4.  Swine-Derived Probiotic Lactobacillus plantarum Inhibits Growth and Adhesion of Enterotoxigenic Escherichia coli and Mediates Host Defense.

Authors:  Jing Wang; Yanxia Zeng; Sixin Wang; Hui Liu; Dongyan Zhang; Wei Zhang; Yamin Wang; Haifeng Ji
Journal:  Front Microbiol       Date:  2018-06-26       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.